Ana P Gonzalez-Rodriguez
Overview
Explore the profile of Ana P Gonzalez-Rodriguez including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
337
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gonzalez-Calle V, Rodriguez-Otero P, Calasanz M, Guijarro M, Martinez-Lopez J, Rosinol L, et al.
Hemasphere
. 2024 Dec;
8(12):e70031.
PMID: 39665068
This study examines the impact of cytogenetic abnormalities and their co-segregation on the prognosis of newly diagnosed multiple myeloma patients. The analysis included 1304 patients from four different GEM-PETHEMA clinical...
2.
Sordo-Bahamonde C, Lorenzo-Herrero S, Gonzalez-Rodriguez A, Martinez-Perez A, Rodrigo J, Garcia-Pedrero J, et al.
Cancers (Basel)
. 2023 Jun;
15(11).
PMID: 37296876
Chemotherapy has been the basis of advanced cancer treatment for decades. This therapy has largely been considered immunosuppressive, yet accumulated preclinical and clinical evidence shows that certain chemotherapeutic drugs, under...
3.
Sordo-Bahamonde C, Lorenzo-Herrero S, Martinez-Perez A, Gonzalez-Rodriguez A, Payer A, Gonzalez-Garcia E, et al.
Cancer Immunol Immunother
. 2023 Apr;
72(7):2529-2539.
PMID: 37041226
Patients with chronic lymphocytic leukemia (CLL) progressively develop marked immunosuppression, dampening innate and adaptive-driven antitumor responses. However, the underlying mechanisms promoting immune exhaustion are largely unknown. Herein, we provide new...
4.
Martinez C, de Haro M, Romero S, Gutierrez A, Domingo-Domenech E, Gonzalez-Rodriguez A, et al.
Ann Hematol
. 2022 Nov;
102(2):429-437.
PMID: 36370191
The AETHERA trial demonstrated that brentuximab vedotin (BV) consolidation after autologous stem cell transplantation (ASCT) in patients with Hodgkin lymphoma (HL) at high risk of relapse/progression increases progression-free survival (PFS)....
5.
Sordo-Bahamonde C, Lorenzo-Herrero S, Gonzalez-Rodriguez A, Payer A, Gonzalez-Garcia E, Lopez-Soto A, et al.
Cancers (Basel)
. 2021 Apr;
13(9).
PMID: 33925565
The inclusion of monoclonal antibodies targeting immune checkpoints such PD-1/PD-L1 or CTLA-4 has revolutionized the landscape of anti-cancer therapy. However, PD-1 and CTLA-4 blockade failed to achieve clinical benefit in...
6.
Sordo-Bahamonde C, Lorenzo-Herrero S, Gonzalez-Rodriguez A, Payer A, Gonzalez-Garcia E, Lopez-Soto A, et al.
Cancers (Basel)
. 2021 Apr;
13(8).
PMID: 33917094
Chronic lymphocytic leukemia (CLL) is characterized by progressive immunosuppression and diminished cancer immunosurveillance. Immune checkpoint blockade (ICB)-based therapies, a major breakthrough against cancer, have emerged as a powerful tool to...
7.
Gonzalez-Rodriguez A, Payer A, Menendez-Suarez J, Sordo-Bahamonde C, Lorenzo-Herrero S, Zanabili J, et al.
J Clin Med
. 2020 Nov;
9(11).
PMID: 33213108
The correlation between progression and the genetic characteristics of Binet stage A patients with chronic lymphocytic leukemia (CLL) detected by whole exome sequencing (WES) was analyzed in 55 patients. The...
8.
Lorenzo-Herrero S, Sordo-Bahamonde C, Bretones G, Payer A, Gonzalez-Rodriguez A, Gonzalez-Garcia E, et al.
Front Immunol
. 2019 Nov;
10:2455.
PMID: 31681329
B-cell receptor (BCR)-dependent signaling is central for leukemia B-cell homeostasis, as underscored by the promising clinical results obtained in patients with chronic lymphocytic leukemia (CLL) treated with novel agents targeting...
9.
Gonzalez-Rodriguez A, Villa-Alvarez M, Sordo-Bahamonde C, Lorenzo-Herrero S, Gonzalez S
J Clin Med
. 2019 Oct;
8(10).
PMID: 31569769
Natural killer (NK) cells have the innate ability to kill cancer cells, however, tumor cells may acquire the capability of evading the immune response, thereby leading to malignancies. Restoring or...
10.
Villa-Alvarez M, Sordo-Bahamonde C, Lorenzo-Herrero S, Gonzalez-Rodriguez A, Payer A, Gonzalez-Garcia E, et al.
Front Immunol
. 2019 Jan;
9:2917.
PMID: 30619281
One of the cardinal features of chronic lymphocytic leukemia (CLL) is its association with a profound immunosuppression. NK cell function is markedly impaired in CLL patients, who show a significant...